List of Excipients in Branded Drug ACETAMINOPHEN EXTENDED RELEASE

Generic Drugs Containing ACETAMINOPHEN EXTENDED RELEASE

Company	Ingredient	NDC	Excipient
NCS HealthCare of KY LLC dba Vangard Labs	acetaminophen	0615-7590	CARNAUBA WAX
NCS HealthCare of KY LLC dba Vangard Labs	acetaminophen	0615-7590	CELLULOSE, MICROCRYSTALLINE
NCS HealthCare of KY LLC dba Vangard Labs	acetaminophen	0615-7590	CROSCARMELLOSE SODIUM
NCS HealthCare of KY LLC dba Vangard Labs	acetaminophen	0615-7590	HYPROMELLOSES

What are the Most Frequently-Used Excipients in ACETAMINOPHEN EXTENDED RELEASE?

# Of NDCs	Excipient
1	CARNAUBA WAX
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	HYPROMELLOSES

Acetaminophen Extended-Release Excipient Strategy and Commercial Opportunities

Last updated: August 6, 2026

Acetaminophen extended-release products compete on dosing convenience, release control, safety communication, manufacturability, and retail differentiation. The strongest commercial opportunity is an 8-hour, 650 mg caplet with robust alcohol-resistant dissolution, low tablet weight, stable supply, and a clearly differentiated package. Excipient selection should prioritize predictable release across fed and fasted conditions, resistance to dose dumping, compressibility, coating performance, and compatibility with high-dose acetaminophen loading.

Scope: This analysis addresses U.S. oral acetaminophen extended-release products, including branded, generic, store-brand, and private-label opportunities. No single patent estate, Orange Book listing, litigation record, or expiration date applies to the entire product category.

What excipient strategy is best for acetaminophen extended release?

A hydrophilic matrix is the most practical platform for a conventional 8-hour acetaminophen product. High-viscosity hypromellose can form a hydrated gel that controls water penetration and drug diffusion while supporting direct compression or wet granulation.

Formulation function	Candidate excipients	Commercial rationale	Primary risks
Release-controlling matrix	Hypromellose, particularly high-viscosity grades	Established regulatory history, scalable supply, adjustable release rate	Variable gel strength, sensitivity to particle size and compression
Filler and compression aid	Microcrystalline cellulose, silicified MCC, lactose, mannitol	Improves tablet strength and throughput	Excessive porosity can accelerate release
Binder	Povidone, copovidone, pregelatinized starch	Supports granule strength and content uniformity	Can alter hydration and release
Disintegrant	Low levels of croscarmellose sodium or sodium starch glycolate	Useful for non-matrix portions and rapid outer-layer breakup	Excessive use can undermine extended release
Lubricant	Magnesium stearate, sodium stearyl fumarate	Supports ejection and tooling performance	Over-lubrication can weaken bonding and slow hydration
Glidant	Colloidal silicon dioxide	Improves flow in high-drug-load blends	May affect blend segregation and tablet hardness
Barrier or functional coating	Ethylcellulose, polyvinyl alcohol, hypromellose film systems	Adds release control, moisture protection, and brand appearance	More process steps and higher scale-up burden
Opacifier and color system	Titanium dioxide where permitted, iron oxides, approved colorants	Supports product identification and light protection	Regulatory and market-specific color restrictions
Seal coat	Hypromellose or polymeric subcoat	Reduces moisture migration and interaction with outer coating	Adds weight and may delay dissolution

A single hydrophilic matrix is generally lower cost than a multiparticulate or coated-pellet system. A bilayer tablet can provide a faster initial release followed by sustained delivery, but it increases tooling, validation, and manufacturing complexity.

How should hypromellose be selected?

The formulation should screen hypromellose by viscosity grade, substitution type, particle-size distribution, and concentration. High-viscosity grades are more likely to support an 8-hour profile, while lower-viscosity grades can provide faster hydration and a shorter release period.

A development program should evaluate:

1. Polymer concentration as a percentage of tablet weight.
2. Acetaminophen particle size and morphology.
3. Granulation endpoint and residual moisture.
4. Compression force, tablet porosity, and tensile strength.
5. Release in multiple dissolution media.
6. Alcohol exposure and mechanical agitation.
7. Release after storage under accelerated and long-term conditions.

The formulation should avoid relying on one excipient to solve both mechanical and release-control problems. MCC can provide structure, while hypromellose controls hydration. Excessive binder or lubricant can make the release profile difficult to adjust.

Which release technologies are commercially attractive?

Hydrophilic matrix tablets

Hydrophilic matrix tablets offer the best balance of cost, patentability, and manufacturing simplicity. They are suitable for high-volume OTC and generic production because they can be made with conventional tablet presses and aqueous or dry granulation equipment.

The commercial limitation is that basic hypromellose matrix technology is widely known. Patent value is more likely to arise from a specific combination of polymer grades, manufacturing conditions, dissolution profile, tablet architecture, or abuse- and alcohol-resistance characteristics than from the generic use of hypromellose.

Hydrophobic matrix tablets

Ethylcellulose, waxes, fatty alcohols, and related hydrophobic materials can reduce water penetration and provide sustained release. These systems can perform well in high-dose formulations but may show greater sensitivity to manufacturing conditions and food effects.

Hydrophobic matrices may support differentiated intellectual property if the product achieves a controlled release profile with reduced variability across fed and fasted states. Their weaknesses include possible incomplete release, higher process temperatures for wax systems, and more difficult scale-up.

Coated multiparticulates

Coated pellets or granules can produce a more uniform gastrointestinal distribution and may reduce the risk of localized drug release. They also allow layering of immediate-release and extended-release fractions.

The platform has higher cost and complexity. It requires fluid-bed coating, tighter particle-size control, and more extensive dissolution testing. Multiparticulates may be attractive for premium products, but they are less compelling for a price-sensitive 650 mg OTC caplet unless they provide a clear benefit.

Osmotic or membrane-controlled systems

Osmotic systems can provide highly controlled release but usually carry higher development and manufacturing costs. They may support stronger formulation patents, but acetaminophen’s mass-market pricing makes the business case difficult unless the delivery system solves a specific safety or pharmacokinetic problem.

What formulation patents can protect acetaminophen extended-release products?

The commercially relevant patent claims are likely to focus on formulation architecture and performance rather than acetaminophen itself, which is an old active ingredient.

Potential claim categories include:

Patent category	Example subject matter	Business value
Composition	Acetaminophen with defined polymer ratios, fillers, binders, or coating systems	Can block closely replicated formulations
Release profile	Defined dissolution limits at selected time points	Useful when linked to a reproducible composition
Dosage form	Bilayer, multilayer, coated core, or multiparticulate structure	Can create design-around cost
Alcohol resistance	Limited acceleration in hydroalcoholic media	Supports safety differentiation
Manufacturing process	Granulation, coating, compression, curing, or moisture-conditioning steps	Can be difficult to detect but may be narrow
Particle engineering	Controlled acetaminophen particle size, morphology, or agglomeration	May improve loading and release consistency
Packaging	Unit-dose or moisture-barrier systems	Usually weaker exclusivity, but commercially useful
Method of use	Eight-hour dosing, pain indications, or reduced dosing frequency	Often vulnerable if the use is clinically conventional

Patent strength depends on claim breadth, technical effect, prior art, enablement, and the availability of practical design-arounds. A claim limited to one hypromellose grade and a narrow concentration range may be easy to avoid. A claim covering a reproducible release profile across multiple polymer systems may be stronger, but it must withstand written-description and enablement scrutiny.

How many patents cover acetaminophen extended release?

There is no meaningful single number for the category. Patent coverage varies by product, manufacturer, jurisdiction, and whether expired formulation patents are included. A proper landscape should separate:

• Active U.S. composition patents.
• Expired formulation patents.
• Pending applications.
• Continuations and divisionals.
• Process patents.
• Design patents.
• Foreign family members.
• Regulatory exclusivity unrelated to patent rights.

Acetaminophen extended-release products should not be analyzed as though the active ingredient has meaningful compound-patent protection. The relevant barriers are formulation, manufacturing, regulatory, branding, and distribution.

What is the FDA regulatory status of acetaminophen extended release?

Acetaminophen is widely marketed as an OTC analgesic and antipyretic. FDA’s OTC framework includes acetaminophen monograph conditions, but an extended-release product must be evaluated against the applicable monograph requirements and any separate FDA requirements for the dosage form and labeling.[1][2]

A product sponsor must establish:

• Identity, strength, quality, and purity.
• Content uniformity for the high-dose tablet.
• Stability through the proposed shelf life.
• Dissolution and release control.
• Manufacturing process validation.
• Labeling that communicates maximum daily use and duplicate-acetaminophen risk.
• Appropriate warnings for liver toxicity and alcohol use.
• Packaging that reduces medication-error risk.

FDA’s inactive ingredient database is an important screening tool, but prior use of an excipient does not automatically establish suitability for a new extended-release composition. The route, dosage form, maximum daily amount, and release mechanism remain relevant.[3]

Does acetaminophen extended release have Orange Book protection?

Orange Book status is product-specific. An OTC monograph product is not equivalent to an NDA product with listed patents. Some acetaminophen extended-release products may be marketed under FDA-approved applications, while others may rely on OTC pathways or abbreviated regulatory routes.

A sponsor should verify:

• Whether the reference product has an NDA.
• Whether patents are listed in the Orange Book.
• Whether the product is eligible for an ANDA.
• Whether a petitioned or monograph-based pathway applies.
• Whether the reference product has an unexpired exclusivity period.
• Whether any listed patent is enforceable against the proposed product.

No Orange Book conclusion should be applied to all acetaminophen extended-release products.

When does acetaminophen extended release lose exclusivity?

There is no category-wide exclusivity date. Acetaminophen has no relevant new-molecule exclusivity in this market. Exclusivity may instead derive from:

• A product-specific formulation patent.
• A method-of-use patent.
• Regulatory exclusivity associated with an approved application.
• Trade secrets covering manufacturing or coating conditions.
• Trademark and trade dress protection.
• Distribution agreements and retailer placement.

For a branded 650 mg extended-release product, the practical generic-entry date depends less on acetaminophen chemistry than on whether the generic can match the reference dissolution profile, labeling, tablet appearance, and manufacturing economics.

What Paragraph IV challenges and generic entry risks exist?

Paragraph IV risk is relevant only where a reference product is supported by an NDA with listed patents and the proposed generic is submitted through an ANDA pathway. A sponsor must assess the specific reference product rather than assume that every OTC acetaminophen product creates a Paragraph IV pathway.

Generic entry risks include:

Risk	Effect on launch
Release-profile mismatch	May cause bioequivalence or regulatory failure
Narrow dissolution specification	Raises formulation iteration costs
Alcohol-induced dose dumping	Creates safety and approval risk
Fed-state variability	May require additional clinical or in vitro work
Tablet-size constraints	Limits drug loading and commercial acceptability
Coating defects	Can create batch failures
Excipient supply disruption	Affects continuity and cost
Labeling differences	Can prevent substitution or weaken retail adoption
Infringement of formulation claims	Can trigger litigation before launch

A generic sponsor can pursue several design-around strategies: alter polymer viscosity or concentration, use a bilayer architecture, change granulation conditions, use a hydrophobic matrix, or develop a coated multiparticulate system. Each design-around must preserve the target release profile and demonstrate acceptable performance.

How should a sponsor manage acetaminophen safety and dose-dumping risk?

Acetaminophen has a narrow margin for consumer misuse because multiple products can contain the ingredient. The commercial product should make the active ingredient, strength, dosing interval, and maximum daily dose conspicuous.

Extended-release development should include:

• Dissolution testing in aqueous and physiologic media.
• Hydroalcoholic testing at relevant alcohol concentrations.
• Mechanical stress testing.
• Evaluation of tablet splitting or crushing.
• Stability under high humidity.
• Assessment of food effects.
• Extractables and leachables review for packaging.
• Human-factors review of the Drug Facts label.

An extended-release product that releases acetaminophen too rapidly after alcohol exposure or physical damage may face regulatory, recall, and liability consequences. The release-control system should be designed to remain robust under foreseeable consumer use and misuse.

Which commercial opportunities are strongest?

Store-brand and private-label substitution

Retailer and private-label products offer the largest volume opportunity. The product can compete on price if the formulation uses a conventional matrix, standard excipients, and existing high-speed tableting capacity.

A private-label strategy should prioritize:

• A common 650 mg platform.
• Multiple package counts.
• Retailer-specific branding.
• Contract manufacturing flexibility.
• Regional packaging configurations.
• A stable supply of hypromellose and coating materials.

Premium dosing convenience

A branded product can justify a higher price through an 8-hour dosing claim, smaller package size, easy-swallow caplet, or differentiated coating. The claim must be supported by the product’s actual pharmacokinetic and dissolution behavior.

Alcohol-resistant formulation

A formulation with limited release acceleration in hydroalcoholic media could support a safety-oriented product position. The claim may be valuable in licensing discussions, although it must be carefully framed to avoid implying that alcohol consumption is safe with acetaminophen.

Pediatric and geriatric formats

Pediatric extended-release acetaminophen is a higher-risk opportunity because dose flexibility, age-specific pharmacokinetics, swallowing ability, and caregiver error complicate the product. Geriatric-friendly caplets, lower-force blister packaging, and improved swallowability may offer a more practical line extension.

Combination products

Combination products with sleep aids, decongestants, or other analgesics can create retail differentiation but increase labeling, interaction, and duplicate-ingredient risks. A combination product also creates a more complex patent and regulatory profile.

How does acetaminophen extended release compare with immediate-release acetaminophen?

Attribute	Immediate-release acetaminophen	Extended-release acetaminophen
Dosing frequency	Typically every 4 to 6 hours	Commonly positioned around an 8-hour interval
Formulation complexity	Low	Moderate to high
Cost of goods	Lower	Higher
Release testing	Conventional dissolution	Multi-time-point, fed/fasted, and dose-dumping evaluation
Patent differentiation	Limited	Greater opportunity through formulation and process claims
Consumer value	Rapid, familiar relief	Convenience and fewer daily doses
Safety communication	Standard acetaminophen warnings	Same core warnings plus release-specific use instructions
Generic competition	Intense	More technical and regulatory barriers
Manufacturing risk	Lower	Higher due to matrix, coating, and process control

The commercial proposition is convenience, not a new analgesic mechanism. The product must demonstrate that the convenience benefit is reliable and understandable to consumers.

What licensing opportunities exist?

Licensing value is highest for technology that solves a measurable problem:

• Robust eight-hour release at a high drug load.
• Reduced alcohol-related release acceleration.
• Low tablet weight with acceptable swallowability.
• Strong compression performance without excessive polymer.
• Stable release after humidity exposure.
• Compatibility with direct compression.
• Reduced fed-state variability.
• Lower-cost coating or granulation process.

A licensee will typically require freedom-to-operate analysis, patent-family review, scale-up data, comparative dissolution, stability data, and evidence that the technology works with commercially available acetaminophen grades.

The strongest deal structure may combine a formulation platform license with contract manufacturing rights, territory-specific exclusivity, or milestone payments tied to FDA acceptance and commercial launch. Basic excipient combinations without demonstrated technical advantages are unlikely to command significant licensing value.

What manufacturing and geographic barriers affect market entry?

The main manufacturing barriers are process consistency and supply-chain control. High-viscosity polymers can vary by supplier and lot. Acetaminophen particle characteristics can affect flow, compression, and release. Coating systems add equipment and process-validation requirements.

Geographic expansion requires review of:

• Country-specific OTC monographs.
• Permitted colorants and titanium dioxide rules.
• Maximum daily dose labeling.
• Local acetaminophen nomenclature, including paracetamol.
• Excipient inventories and compendial standards.
• Packaging and child-resistant closure requirements.
• Product registration pathways.
• Patent rights in each jurisdiction.

A U.S. formulation may require changes for Canada, the European Union, the United Kingdom, Australia, or emerging markets. Patent protection and regulatory status must be evaluated separately by country.

What patent litigation affects acetaminophen extended release?

Litigation cannot be assigned to the category without identifying the reference product, NDA holder, patent numbers, and proposed generic. The most likely litigation theories are infringement of formulation, dissolution, manufacturing-process, or method-of-use claims.

A practical freedom-to-operate review should search:

1. U.S. and foreign patent families covering acetaminophen modified release.
2. Assignments to branded manufacturers and excipient technology companies.
3. Continuations with later-issued claims.
4. ANDA litigation under the Hatch-Waxman framework.
5. Post-grant review, inter partes review, and opposition proceedings.
6. Settlement agreements that restrict generic launch timing.

Trade-secret exposure may be more important than patent exposure where the competitive advantage lies in granulation endpoint, coating cure, polymer conditioning, or process controls that are difficult to reverse engineer.

Key Takeaways

• A hydrophilic hypromellose matrix is the most commercially practical platform for an eight-hour acetaminophen product.
• The strongest differentiation is likely to come from release robustness, alcohol resistance, low tablet weight, and manufacturing efficiency.
• Acetaminophen itself does not provide meaningful new-molecule patent protection.
• Patent value resides in formulation architecture, release performance, manufacturing process, and selected method-of-use claims.
• Orange Book, Paragraph IV, exclusivity, and litigation analysis must be performed at the individual product and NDA level.
• Private-label and store-brand products offer the largest volume opportunity, while premium products require a defensible consumer benefit.
• Safety labeling and duplicate-ingredient controls are central commercial and regulatory issues.
• The best licensing targets are technologies with validated scale-up data and a clear design-around advantage over conventional hypromellose matrices.

FAQs

Can acetaminophen extended release use the same excipients as immediate-release tablets?

Some excipients can be shared, including MCC, magnesium stearate, colloidal silicon dioxide, and film-coating materials. Extended release requires a validated release-controlling system, usually based on a polymer matrix or functional coating.

Is hypromellose patentable in an acetaminophen extended-release product?

Hypromellose itself is well established and generally cannot support broad, novel protection. Patentability may arise from a specific polymer combination, concentration range, tablet architecture, manufacturing process, or demonstrated release and alcohol-resistance profile.

What tablet strength is most commercially attractive?

A 650 mg extended-release caplet has the clearest U.S. commercial positioning because it aligns with established eight-hour arthritis-pain and extended-release products. Lower strengths may support flexible dosing but can increase tablet count.

Can acetaminophen extended release be sold as a monograph OTC product?

The answer depends on the product design, dosage form, claims, labeling, and applicable FDA requirements. A sponsor must determine whether the product fits the OTC monograph framework or requires an approved application.

Are biosimilars relevant to acetaminophen extended release?

No. Acetaminophen is a chemically synthesized small molecule. Competitive entry occurs through generic, OTC, private-label, or branded line-extension pathways, not through biosimilar approval.

References

1. U.S. Food and Drug Administration. (n.d.). OTC monograph M013: Internal analgesic, antipyretic, and antirheumatic drug products. FDA.

2. U.S. Food and Drug Administration. (2022). Acetaminophen information. FDA.

3. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. FDA.

4. U.S. Food and Drug Administration. (1997). SUPAC-MR: Modified release solid oral dosage forms scale-up and postapproval changes. FDA, Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (2000). Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. FDA, Center for Drug Evaluation and Research.

6. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.